Published in J Med Chem on January 19, 1996
Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells. Biochem J (1997) 1.57
Endocannabinoid binding to the cannabinoid receptors: what is known and what remains unknown. Curr Med Chem (2010) 0.95
Inhibition of monoamine oxidase activity by cannabinoids. Naunyn Schmiedebergs Arch Pharmacol (2010) 0.88
The role of fluorine substitution in the structure-activity relationships (SAR) of classical cannabinoids. Bioorg Med Chem Lett (2007) 0.80
Novel, potent THC/anandamide (hybrid) analogs. Bioorg Med Chem (2007) 0.78
International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev (2002) 8.50
Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol (1995) 8.09
Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A (2001) 7.15
Regulation of adipose tissue pyruvate dehydrogenase by insulin and other hormones. Biochem J (1971) 4.50
Stimulation by calcium ions of pyruvate dehydrogenase phosphate phosphatase. Biochem J (1972) 4.05
Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci U S A (1999) 3.54
Improved lactose digestion and intolerance among African-American adolescent girls fed a dairy-rich diet. J Am Diet Assoc (2000) 2.94
Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther (1996) 2.90
Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol Biochem Behav (1991) 2.57
The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J Pharmacol Exp Ther (1994) 2.55
Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J Pharmacol Exp Ther (1993) 2.40
Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther (2000) 2.26
Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol (2001) 2.22
Role of adenine and guanine nucleotides in the activity and response of adenylate cyclase systems to hormones: evidence for multisite transition states. Adv Cyclic Nucleotide Res (1975) 2.06
Differential role of nicotinic acetylcholine receptor subunits in physical and affective nicotine withdrawal signs. J Pharmacol Exp Ther (2008) 2.04
Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain. J Neurochem (2000) 2.04
Mechanisms regulating adipose-tissue pyruvate dehydrogenase. Biochem J (1972) 2.01
Continuous infusion of pyridostigmine in the management of myasthenic crisis. Crit Care Med (1993) 1.99
Structure-activity relationships of indole- and pyrrole-derived cannabinoids. J Pharmacol Exp Ther (1998) 1.97
Cannabis: pharmacology and toxicology in animals and humans. Addiction (1996) 1.89
Distinct patterns of DeltaFosB induction in brain by drugs of abuse. Synapse (2008) 1.87
Cannabinoid-induced hypotension and bradycardia in rats mediated by CB1-like cannabinoid receptors. J Pharmacol Exp Ther (1997) 1.87
Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol (2007) 1.85
In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J Pharmacol Exp Ther (1996) 1.85
Nicotine dependence and reward differ between adolescent and adult male mice. J Pharmacol Exp Ther (2007) 1.81
Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from delta 9-tetrahydrocannabinol. J Pharmacol Exp Ther (1992) 1.76
Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. Nature (1997) 1.76
Cardiovascular effects of anandamide in anesthetized and conscious normotensive and hypertensive rats. Hypertension (1997) 1.75
3-(1',1'-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. Bioorg Med Chem (1999) 1.73
Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide. Eur J Pharmacol (1995) 1.72
Characterization of spontaneous and precipitated nicotine withdrawal in the mouse. J Pharmacol Exp Ther (2003) 1.64
Pharmacology and stereoselectivity of structurally novel cannabinoids in mice. J Pharmacol Exp Ther (1988) 1.58
Discovery and characterization of endogenous cannabinoids. Life Sci (1999) 1.56
Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement. J Pharmacol Exp Ther (1996) 1.55
Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB(1) and CB(2) receptor binding. Drug Alcohol Depend (2000) 1.55
Identification of the first trans-(3R,4R)- dimethyl-4-(3-hydroxyphenyl)piperidine derivative to possess highly potent and selective opioid kappa receptor antagonist activity. J Med Chem (2001) 1.54
Structure-activity relationships in cannabinoids. Pharmacol Rev (1986) 1.52
Development of cross-tolerance between delta 9-tetrahydrocannabinol, CP 55,940 and WIN 55,212. J Pharmacol Exp Ther (1994) 1.52
Comparative receptor binding analyses of cannabinoid agonists and antagonists. J Pharmacol Exp Ther (1998) 1.48
A simple enzymic method for the synthesis of adenosine 5'-[alpha-32P]triphosphate on a preparative scale. Biochem J (1977) 1.47
Evidence that the antinociceptive tail-flick response is produced independently from changes in either tail-skin temperature or core temperature. Pain (1993) 1.46
Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents. J Pharmacol Exp Ther (1992) 1.41
Delta9-tetrahydrocannbinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice. J Pharmacol Exp Ther (2005) 1.39
Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats. Psychopharmacology (Berl) (1995) 1.38
Structural determinants of the partial agonist-inverse agonist properties of 6'-azidohex-2'-yne-delta8-tetrahydrocannabinol at cannabinoid receptors. Br J Pharmacol (1999) 1.37
Cost and survival results of critical care regionalization for Medicare patients. Crit Care Med (1989) 1.37
Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. J Pharmacol Exp Ther (1998) 1.37
Cannabinoid tolerance and dependence. Handb Exp Pharmacol (2005) 1.35
Insulin inhibits the cholera-toxin-catalysed ribosylation of a Mr-25000 protein in rat liver plasma membranes. Biochem J (1985) 1.35
Racial differences in bone turnover and calcium metabolism in adolescent females. J Clin Endocrinol Metab (2003) 1.31
Insulin activates pyruvate dehydrogenase in rat epididymal adipose tissue. Nat New Biol (1971) 1.31
Evaluation of cannabinoid receptor agonists and antagonists using the guanosine-5'-O-(3-[35S]thio)-triphosphate binding assay in rat cerebellar membranes. J Pharmacol Exp Ther (1998) 1.31
Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation. Mol Pharmacol (1992) 1.30
Evaluation of the cannabinoid CB2 receptor-selective antagonist, SR144528: further evidence for cannabinoid CB2 receptor absence in the rat central nervous system. Eur J Pharmacol (1999) 1.30
Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects. Eur J Pharmacol (2001) 1.29
The antinociceptive effects of alpha7 nicotinic agonists in an acute pain model. Neuropharmacology (2000) 1.28
Antagonism of the discriminative stimulus effects of delta 9-tetrahydrocannabinol in rats and rhesus monkeys. J Pharmacol Exp Ther (1995) 1.28
Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice. J Pharmacol Exp Ther (2001) 1.27
Metabolism of pyruvate and malate by isolated fat-cell mitochondria. Biochem J (1971) 1.26
Effects of insulin and adrenaline on rat epididymal-fat-pad pyruvate dehydrogenase. Biochem J (1971) 1.26
Delta 9-tetrahydrocannabinol impairs spatial memory through a cannabinoid receptor mechanism. Psychopharmacology (Berl) (1996) 1.25
The biodisposition and metabolism of anandamide in mice. J Pharmacol Exp Ther (1997) 1.24
Soy isoflavones do not affect bone resorption in postmenopausal women: a dose-response study using a novel approach with 41Ca. J Clin Endocrinol Metab (2006) 1.24
Antiresorptive effects of phytoestrogen supplements compared with estradiol or risedronate in postmenopausal women using (41)Ca methodology. J Clin Endocrinol Metab (2009) 1.22
Antinociceptive responses to nicotinic acetylcholine receptor ligands after systemic and intrathecal administration in mice. J Pharmacol Exp Ther (1998) 1.22
Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor. J Med Chem (1996) 1.19
The effect of insulin on plasma-membrane and mitochondrial-membrane potentials in isolated fat-cells. Biochem J (1981) 1.19
Pharmacological specificity of the discriminative stimulus effects of delta 9-tetrahydrocannabinol in rhesus monkeys. Drug Alcohol Depend (1995) 1.18
Calcium retention in relation to calcium intake and postmenarcheal age in adolescent females. Am J Clin Nutr (1997) 1.17
Spinal and supraspinal components of cannabinoid-induced antinociception. J Pharmacol Exp Ther (1991) 1.16
Larvicidal and mosquito repellent activities of Pine (Pinus longifolia, family: Pinaceae) oil. J Vector Borne Dis (2005) 1.16
Time course for the induction and maintenance of tolerance to Delta(9)-tetrahydrocannabinol in mice. Drug Alcohol Depend (2000) 1.16
Relative efficacy of various oils in repelling mosquitoes. Indian J Malariol (1995) 1.16
Stereochemical effects of 11-OH-delta 8-THC-dimethylheptyl in mice and dogs. Pharmacol Biochem Behav (1989) 1.15
Nicotine-induced antinociception in rats and mice: correlation with nicotine brain levels. J Pharmacol Exp Ther (1982) 1.15
Do functional relationships exist between 5-HT1A and 5-HT2 receptors? Pharmacol Biochem Behav (1990) 1.15
Identification of an opioid kappa receptor subtype-selective N-substituent for (+)-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine. J Med Chem (1998) 1.14
The psychoactive plant cannabinoid, Delta9-tetrahydrocannabinol, is antagonized by Delta8- and Delta9-tetrahydrocannabivarin in mice in vivo. Br J Pharmacol (2007) 1.13
Pharmacological characterization of cannabinoids in the elevated plus maze. J Pharmacol Exp Ther (1990) 1.13
CB1 receptor antagonist precipitates withdrawal in mice exposed to Delta9-tetrahydrocannabinol. J Pharmacol Exp Ther (1998) 1.12
Optically pure (+)-nicotine from (+/-)-nicotine and biological comparisons with (-)-nicotine. J Med Chem (1979) 1.12
Transient complexes. A new structural model for the activation of adenylate cyclase by hormone receptors (guanine nucleotides/irradiation inactivation). Biochem J (1979) 1.11
Pharmacology of some marijuana constituents and 2 heterocyclic analogues. Nature (1970) 1.11
Neurobiology of marijuana abuse. Trends Pharmacol Sci (1992) 1.11
Genetic approaches identify differential roles for alpha4beta2* nicotinic receptors in acute models of antinociception in mice. J Pharmacol Exp Ther (2007) 1.10
Manipulation of the tetrahydrocannabinol side chain delineates agonists, partial agonists, and antagonists. J Pharmacol Exp Ther (1999) 1.10
Characterization of the lipophilicity of natural and synthetic analogs of delta 9-tetrahydrocannabinol and its relationship to pharmacological potency. J Pharmacol Exp Ther (1990) 1.10
Interactions between THC and cannabidiol in mouse models of cannabinoid activity. Psychopharmacology (Berl) (2006) 1.09
Agonist-antagonist characterization of 6'-cyanohex-2'-yne-delta 8-tetrahydrocannabinol in two isolated tissue preparations. Eur J Pharmacol (1996) 1.09
Status epilepticus causes a long-lasting redistribution of hippocampal cannabinoid type 1 receptor expression and function in the rat pilocarpine model of acquired epilepsy. Neuroscience (2007) 1.09
Peak bone mass in young women. J Bone Miner Res (1995) 1.09
Age-dependent differences in nicotine reward and withdrawal in female mice. Psychopharmacology (Berl) (2008) 1.08
Synthesis, nicotinic acetylcholine receptor binding, and antinociceptive properties of 2-exo-2-(2'-substituted 5'-pyridinyl)-7-azabicyclo[2.2.1]heptanes. Epibatidine analogues. J Med Chem (2001) 1.08